- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03665506
Trifluridin/tipirACil in meTastatIc Colorectal Cancer (TACTIC)
November 19, 2021 updated by: Servier Deutschland GmbH
A Non-interventional Study to Assess Effectiveness and Safety of Trifluridin/Tipiracil in Patients With Metastatic Colorectal Cancer
A non-interventional, prospective, open, multicenter study in Germany in patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies and with decision for treatment with trifluridin/tipiracil.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this NIS, after market approval of trifluridin/tipiracil as treatment for mCRC patients who have been previously treated with, or are not considered candidates for, available therapies, is to evaluate effectiveness, QoL, treatment details and safety of trifluridin/tipiracil treatment in a real-world setting.
In addition, therapy management and health economic parameters regarding trifluridin/tipiracil treatment will be assessed.
Study Type
Observational
Enrollment (Actual)
315
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 10707
- Onkologische Schwerpunktpraxis Kurfürstendamm
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF (vascular endothelial growth factor) agents, and anti-EGFR (epidermal growth factor receptor) agents and with decision for treatment with trifluridin/tipiracil.
Description
Inclusion Criteria:
- Aged 18 years or older.
- Patients with mCRC who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.
- Indication for treatment as assessed by the treating physician.
- Decision for treatment with trifluridin/tipiracil.
- Signed written informed consent.
- Criteria according to current Summary of Product Characteristics (SmPC) for patients treated with trifluridin/tipiracil.
- Ability to read and understand German.
Exclusion Criteria:
- Contraindications according to SmPC for metastatic colorectal cancer patients treated with trifluridin/tipiracil.
- Participation in a clinical trial within 30 days prior to enrollment or simultaneous participation in a clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: Baseline up to 3 years
|
time from first administration of trifluridin/tipiracil to death from any cause
|
Baseline up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: Baseline up to 3 years
|
PFS: time from first administration of trifluridin/tipiracil to disease progression or death from any cause
|
Baseline up to 3 years
|
Overall response rate
Time Frame: Baseline up to 3 years
|
ORR: the proportion of patients whose best response was a complete or partial response
|
Baseline up to 3 years
|
Disease control rate 8 weeks
Time Frame: Baseline up to 3 years
|
DCR-8: the proportion of patients with a best response of complete or partial response or stable disease, with the assessment of stable disease made at least 8 weeks after first administration of trifluridin/tipiracil
|
Baseline up to 3 years
|
Trifluridin/tipiracil treatment details
Time Frame: Baseline
|
Line of Trifluridin/Tipiracil treatment (Descriptive statistics using frequency tables will be used to assess the number of prior palliative systemic antineoplastic treatment regimen)
|
Baseline
|
Trifluridin/tipiracil treatment details
Time Frame: Baseline up to 3 years
|
Treatment duration
|
Baseline up to 3 years
|
Trifluridin/tipiracil treatment details
Time Frame: Baseline up to 3 years
|
Dose intensity (absolute and relative)
|
Baseline up to 3 years
|
Trifluridin/tipiracil treatment details
Time Frame: Baseline up to 3 years
|
Treatment sequence (previous and subsequent therapies in relation to Trifluridin/Tipiracil treatment) (Descriptive statistics using frequency tables will be used to assess previous and subsequent palliative systemic antineoplastic treatment regimen used.)
|
Baseline up to 3 years
|
AEs and SAEs according to NCI CTCAE
Time Frame: Baseline up to 3 years
|
AEs and SAEs according to NCI CTCAE
|
Baseline up to 3 years
|
Safety laboratory values of participants
Time Frame: Baseline up to 3 years
|
By-patient display of all safety laboratory results captured as per clinical routine (e.g.
CEA, CA 19-9, haemoglobin, neutrophils absolute, lymphocytes count, platelets count, leukocytes count, alkaline phosphatase, ALT (GPT), AST (GOT), bilirubin total and serum creatinine).
In addition, CTCAE grades of neutrophils, white blood cell count, platelets, haemoglobin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, alkaline phosphatase and creatinine will be presented using frequencies and percentages for each visit.
Shift tables opposing CTCAE grades during treatment to baseline CTCAE grades of the mentioned parameters will also be presented per visit using frequencies and percentages.
|
Baseline up to 3 years
|
Therapy management (use of relevant supportive medications)
Time Frame: Baseline up to 3 years
|
Number of patients receiving G-CSFs for prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia (Frequencies)
|
Baseline up to 3 years
|
Patient-reported outcomes (PROs) on quality of life (QoL)
Time Frame: Baseline up to 3 years
|
PRO-CTCAE: Questionnaire PRO-CTCAE is used to determine patients' symptomatic toxicity.
Item cluster scores of PRO-CTCAE questionnaire at each visit and change from baseline of scores.
|
Baseline up to 3 years
|
Patient-reported outcomes (PROs) on quality of life (QoL)
Time Frame: Baseline up to 3 years
|
EQ-5D-5L: Questionnaire EQ-5D-5L is used to determine patients' health related quality of life.
EQ-5D-5L index and visual analogue score at each visit and change from baseline for both, index and visual analogue score.
|
Baseline up to 3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to deterioration of the ECOG performance status
Time Frame: Baseline up to 3 years
|
Baseline up to 3 years
|
|
Assessment of health economic parameters
Time Frame: Baseline up to 3 years
|
Incidence of hospitalization (Frequencies)
|
Baseline up to 3 years
|
Assessment of health economic parameters
Time Frame: Baseline up to 3 years
|
Frequency of hospitalization (Frequencies)
|
Baseline up to 3 years
|
Assessment of health economic parameters
Time Frame: Baseline up to 3 years
|
Total duration of hospital stays per patient (descriptive statistics)
|
Baseline up to 3 years
|
Assessment of health economic parameters
Time Frame: Baseline up to 3 years
|
Reasons for hospitalizations per patient and per case (Frequencies)
|
Baseline up to 3 years
|
Assessment of health economic parameters
Time Frame: Baseline up to 3 years
|
Number of consultations of various medical specialists
|
Baseline up to 3 years
|
Assessment of health economic parameters
Time Frame: Baseline up to 3 years
|
Incidence of home care (Frequencies)
|
Baseline up to 3 years
|
Assessment of health economic parameters
Time Frame: Baseline up to 3 years
|
Location of terminal care (Frequencies)
|
Baseline up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 25, 2018
Primary Completion (Actual)
August 2, 2021
Study Completion (Actual)
August 2, 2021
Study Registration Dates
First Submitted
August 26, 2018
First Submitted That Met QC Criteria
September 7, 2018
First Posted (Actual)
September 11, 2018
Study Record Updates
Last Update Posted (Actual)
November 22, 2021
Last Update Submitted That Met QC Criteria
November 19, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites
- Trifluridine
Other Study ID Numbers
- IOM-040380
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
Symphogen A/STerminatedCarcinoma | Metastatic Colorectal Cancer | Colorectal Cancer MetastaticUnited States, Spain, Germany, Italy
Clinical Trials on Trifluridin/Tipiracil
-
Wuhan Union Hospital, ChinaRecruitingColorectal Neoplasms MalignantChina
-
Roswell Park Cancer InstitutePfizerRecruitingAdvanced Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Clinical Stage III... and other conditionsUnited States
-
Centre Georges Francois LeclercRecruiting
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Colorectal Carcinoma | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon... and other conditionsUnited States
-
UNICANCERActive, not recruitingMetastatic Colorectal CancerFrance, Belgium
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)Active, not recruitingRecurrent Colon Carcinoma | Metastatic Colorectal Carcinoma | Stage IV Colon Cancer AJCC v7 | Stage IVA Colon Cancer AJCC v7 | Stage IVB Colon Cancer AJCC v7 | Refractory Colorectal CarcinomaUnited States
-
Providence Health & ServicesTaiho OncologyCompletedRectal CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedCholangiocarcinoma | Stage III Gallbladder Cancer AJCC v7 | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IV Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage IVB Gallbladder Cancer AJCC v7United States